Volume : 12, Issue : 08, August- 2025
Title:
THE COMPARATIVE ANALYSIS OF EFFICACY AND SAFETY PARAMETERS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE: A NARRATIVE STUDY
Authors :
Sardar Khizar Hayat, Umair Arshad, Momina Shahzad, FNU Abdul Rehman, Usman Safdar, Syed Ali Ahsan
Abstract :
Background:Basal insulin analogues are essential to the management of diabetes mellitus, which gives a sympathy glycemic control with lesser risk of hypoglycemia. In these terms, Insulin Degludec and Insulin Glargine have been broadly contrasting in clinical trials to find out the differences in effectiveness, safety, and patient results.
Objective:To study and arrange current evidence on the comparative effectiveness and safety profiles of IDeg and IGlar, which focuses on glycemic control, hypoglycemia risk, and patient-reported results.
Methods:A descriptive study of randomized controlled trials, meta-analyses, and real-world experimental studies published between 2013 and 2024 was conducted. Databases searched included PubMed, Scopus, and Cochrane Library. Studies were included if they compared IDeg and IGlar in type 1 or type 2 diabetes patients.
Results:Evidence constantly illustrates that IDeg provides non-inferior glycemic control compared to IGlar, with some studies showing superior reductions in HbA1c. IDeg is linked with a remarkably lower risk of nocturnal and severe hypoglycemia. Both insulins highlight similar safety profiles regarding weight gain and adverse events.
Conclusion:While both IDeg and IGlar are effectiveness in basal insulins, IDeg will give advantages in reduction of hypoglycemia risk, specifically improved patient attachment and standard of life.
Keywords: IDeg, Glycemic control, Hypoglycemic, chronic, Diabetes
Cite This Article:
Please cite this article in press Sardar Khizar Hayat et al., The Comparative Analysis Of Efficacy And Safety Parameters Of Insulin Degludec Versus Insulin Glargine: A Narrative Study., Indo Am. J. P. Sci, 2025; 12(08).
Number of Downloads : 10
References:
1. Alhmoud, E. N., Saad, M. O., & Omar, N. E. (2024). Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. Frontiers in Endocrinology, 14, 1285147.
2. Kamrul-Hasan, A. B. M., Borozan, S., Fernandez, C. J., Dutta, D., Nagendra, L., & Pappachan, J. M. (2025). Thrice-Weekly Insulin Degludec Versus Once-Daily Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. British Journal of Hospital Medicine, 1-16.
3. Rosenstock, J., Bajaj, H. S., Lingvay, I., & Heller, S. R. (2024). Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ Open Diabetes Research & Care, 12(3).
4. Raja, S., Raja, A., Ali, A., & Asghar, M. S. (2025). Once-weekly Basal Insulin Fc versus daily insulin degludec for glycemic control in diabetes: a systematic review, meta-analysis, and meta-regression. Journal of Diabetes & Metabolic Disorders, 24(1), 86.
5. Home, P., Lauand, F., Djaballah, K., Li, X. T., Hafidh, K., Mehta, R., … & Pourrahmat, M. M. (2025). Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies. Diabetes, Obesity and Metabolism, 27(6), 3410-3418.
6. Billings, L. K., Asong, M., Bøg, M., Clancy, S., Kruse, C., de Laguiche, E., & Maddaloni, E. (2025). AUGMENTed Real-World Data Enhances Comparative Efficacy Between Once-Weekly Insulin Icodec with Dosing Guide App Versus Once-Daily Insulin Glargine U300 in Insulin-Naive Type 2 Diabetes. Diabetes Therapy, 16(2), 227-239.
7. Rosario, N., Hunger, C., Pettijohn, A., Whaley, K. B., Pabon, A., Hohl, V., … & Wollen, J. (2025). Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine. Journal of Primary Care & Community Health, 16, 21501319251327318.
8. Njei, B., Al-Ajlouni, Y., Lemos, S. Y., Ugwendum, D., Ameyaw, P., Njei, L. P., & Boateng, S. (2024). Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus, 16(10).
9. Kowalczyk, E., Gorczyca-Głowacka, I., Stupecki, G., Ciba-Stemplewska, A., Dolecka-Ślusarczyk, M., & Wolak, P. (2025). Impact of Various Oral Hypoglycemic Agents on Hepatic Steatosis Reduction in MASLD and Type 2 Diabetes: Exploring the Bidirectional Relationship. A Narrative Review. Clinical Diabetology.
10. Salmen, T., Potcovaru, C. G., Bica, I. C., Giglio, R. V., Patti, A. M., Stoica, R. A., … & Stoian, A. P. (2024). Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. Pharmaceuticals, 17(10), 1322.
11. Marino, E. C., Momesso, D., Toyoshima, M. T. K., de Almeida, M. F. O., Schaan, B. D., Negretto, L. A. F., … & Bertoluci, M. C. (2025). Screening and management of hospital hyperglycemia in non-critical patients: a position statement from the Brazilian Diabetes Society (SBD). Diabetology & Metabolic Syndrome, 17(1), 54.
12. Cowart, K., & Carris, N. W. (2025). Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?. Diabetes, Obesity and Metabolism.
13. Tang, A. S. P., Hsu, J. T. Y., Chong, S. K. S., Quek, J., Shek, G., Sulaimi, F., … & Chew, N. W. (2025). Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety. Cardiovascular diabetology, 24(1), 285.
14. Rangwala, H. S., Fatima, H., Ali, M., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., & Abbas, S. R. (2024). Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. Journal of Diabetes & Metabolic Disorders, 23(1), 1199-1222.
15. Hassanein, M., Shaltout, I., Malek, R., Assaad Khalil, S., Ballout, H., Annabi, F., & Shereen, M. (2024). Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes mellitus during the period of Ramadan in four countries (Egypt, Jordan, Lebanon, and Turkey): a prospective observational study. Current Diabetes Reviews, 20(5), 137-147.